Journal
CANCER LETTERS
Volume 520, Issue -, Pages 201-212Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.07.020
Keywords
Medulloblastoma; FACT; APE1; DNA repair; CBL0137
Categories
Funding
- National Institutes of Health/National Cancer Institute [R03 CA235214]
- Pediatric Cancer Research Group pilot grant [LB905]
- Child Health Research Institute
- National Institute for General Medical Science (NIGMS) [INBRE-P20GM103427-14, COBRE-1P30GM110768-01]
- Team Jack Foundation
Ask authors/readers for more resources
MB tumors exhibit elevated levels of the nucleosome remodeling FACT complex and DNA repair enzyme APE1, which promote repair of DNA damage induced by radiation and cisplatin. Targeting the FACT complex with CBL0137 enhances the potency of cisplatin and radiation, leading to the suppression of MB tumor growth.
Medulloblastoma (MB) is a malignant pediatric brain tumor with a poor prognosis. Post-surgical radiation and cisplatin-based chemotherapy have been a mainstay of treatment, which often leads to substantial neuro-cognitive impairments and morbidity, highlighting the need for a novel therapeutic target to enhance the sensitivity of MB tumors to cytotoxic therapies. We performed a comprehensive study using a cohort of 71 MB patients' samples and pediatric MB cell lines and found that MB tumors have elevated levels of nucleosome remodeling FACT (FAcilitates Chromatin Transcription) complex and DNA repair enzyme AP-endonuclease1 (APE1). FACT interacts with APE1 and facilitates recruitment and acetylation of APE1 to promote repair of radiation and cisplatin-induced DNA damage. Further, levels of FACT and acetylated APE1 both are correlate strongly with MB patients' survival. Targeting FACT complex with CBL0137 inhibits DNA repair and alters expression of a subset of genes, and significantly improves the potency of cisplatin and radiation in vitro and in MB xenograft. Notably, combination of CBL0137 and cisplatin significantly suppressed MB tumor growth in an intracranial orthotopic xenograft model. We conclude that FACT complex promotes chemo-radiation resistance in MB, and FACT inhibitor CBL0137 can be used as a chemo-radiation sensitizer to augment treatment efficacy and reduce therapy-related toxicity in high-risk pediatric patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available